1. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
by Issa F. Khouri, Peter McLaughlin, Rima M. Saliba, Chitra Hosing, Martin Korbling, Ming S. Lee, L. Jeffrey Medeiros, Luis Fayad, Felipe Samaniego, Amin Alousi, Paolo Anderlini, Daniel Couriel, Marcos de Lima, Sergio Giralt, Sattva S. Neelapu, Naoto T. Ueno, Barry I. Samuels, Fredrick Hagemeister, Larry W. Kwak, and Richard E. Champlin
Blood
Volume 111(12):
June 15, 2008
©2008 by American Society of Hematology

2. Peripheral blood CD19+ recovery after transplantation.
Issa F. Khouri et al. Blood 2008;111:
©2008 by American Society of Hematology

3. Proportion of patients with normal immunoglobulin (Ig) levels after transplantation.
Issa F. Khouri et al. Blood 2008;111:
©2008 by American Society of Hematology

4. OS (solid line) and PFS were 85% and 83%, respectively, with a median follow-up of 60 months (range, months).
OS (solid line) and PFS were 85% and 83%, respectively, with a median follow-up of 60 months (range, months).
Issa F. Khouri et al. Blood 2008;111:
©2008 by American Society of Hematology

5. Incidence of severe acute GVHD after nonmyeloablative stem cell transplantation.
Issa F. Khouri et al. Blood 2008;111:
©2008 by American Society of Hematology

6. Incidence (—) and survival duration (----) of patients with chronic extensive and limited GVHD.
Issa F. Khouri et al. Blood 2008;111:
©2008 by American Society of Hematology